| Name | Title | Contact Details |
|---|
The world leader in addiction treatment with over 20 years of experience and a patient-focused approach. We didn`t become the world leader in addiction treatment overnight. Our endeavor started small, with one singular focus – to intimately understand the journey of individuals suffering with addiction. People with addiction are often stereotyped and discounted, creating an environment where many are under-diagnosed, undertreated and under-supported. They`re often unaware of their treatment options, have limited access to treatment, or simply don`t seek it out because they`re afraid of being stigmatized. Since our inception, we have actively partnered with healthcare professionals, the public health community, policy makers, and payers to humanize people suffering from addiction and to treat addiction as a chronic, relapsing medical condition rather than a social disorder. We believe that people with addiction should be treated as patients, just like people with other chronic diseases. The past two decades have been marked by strong growth and an expansion into more than 40 countries. While treatment for opioid use disorder has seen much innovation, we at Indivior are building on our intimate understanding of the patient journey to further advance addiction treatment including opiate overdose, alcohol use disorders, and co-occurring conditions such as schizophrenia by bringing to market novel treatment solutions worldwide. We at Indivior are on an endeavor – one that is focused on individual patients around the world. Our name reflects this as the key words individual and endeavor harmoniously blend together. It represents and empathizes with the often difficult journey each individual patient takes to overcome the challenges of addiction – a chronic relapsing disease. The patient continues to drive our decisions. Our guiding principles foster a corporate culture of trust, innovation, and a pioneering spirit. We work with the urgency and zeal required to achieve our vision that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction.
ACEA Biosciences is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of- the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools and therapeutics. Rosetta currently commercializes a full range of microRNA-based molecular diagnostics. Rosetta's cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab.
Connect Biopharma (Nasdaq: CNTB) is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research. With operations and expertise in China, the United States and Australia and clinical development activities in those geographies as well as Europe, Connect Biopharma is building a rich pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. Our core expertise is in the use of functional cellular assays with T cells to screen and discover potent drug candidates against immune targets. Our two most advanced clinical-stage programs include highly differentiated product candidates against validated targets.
Pharmgate Animal Health is headquartered in Wilmington, North Carolina, and provides innovative and high-quality products that help the livestock industry optimize animal health, efficiency and production. Pharmgate Animal Health is celebrating its 10th Anniversary in 2018. The company`s pharmaceutical production facilities are located in Omaha, Nebraska with vaccine research and manufacturing operations based in St. Paul, Minnesota.